β₂-Adrenergic receptor agonists: a new treatment for diabetic kidney disease?

Zhiwen Liu¹, Zheng Dong^{2

3}

Affiliations

¹ Department of Nephrology, The Second Xiangya Hospital at Central South University, Hunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, People's Republic of China.
² Department of Cellular Biology and Anatomy, Medical College of Georgia at Augusta University, Augusta, Georgia, United States.
³ Charlie Norwood Veterans Affairs Medical Center, Augusta, Georgia, United States.

Free article

Editorial

Zhiwen Liu et al. Am J Physiol Renal Physiol. 2024.

Free article

. 2024 Jan 1;326(1):F1-F2.

doi: 10.1152/ajprenal.00299.2023. Epub 2023 Nov 2.

Zhiwen Liu¹, Zheng Dong^{2

3}

¹ Department of Nephrology, The Second Xiangya Hospital at Central South University, Hunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, People's Republic of China.
² Department of Cellular Biology and Anatomy, Medical College of Georgia at Augusta University, Augusta, Georgia, United States.
³ Charlie Norwood Veterans Affairs Medical Center, Augusta, Georgia, United States.

No abstract available

Keywords: diabetic kidney disease; β2-adrenergic receptor.

Comment on

β₂-Adrenergic receptor agonists as a treatment for diabetic kidney disease.
Arif E, Medunjanin D, Solanki A, Zuo X, Su Y, Dang Y, Winkler B, Lerner K, Kamal AI, Palygin O, Cornier MA, Wolf BJ, Hunt KJ, Lipschutz JH. Arif E, et al. Am J Physiol Renal Physiol. 2024 Jan 1;326(1):F20-F29. doi: 10.1152/ajprenal.00254.2023. Epub 2023 Nov 2. Am J Physiol Renal Physiol. 2024. PMID: 37916289 Free PMC article.